Orexigen Therapeutics Inc News

Orexigen Therapeutics Inc News From AOL News

Contrave Rejected: What Does the FDA Have Against Diet Pills?

Today the Food and Drug Administration declined to approve Contrave, a new prescription weight-loss drug that an FDA advisory panel had recommended for approval. The FDA ruling on Contrave told drugmaker Orexigen Therapeutics that the agency was concerned about long-term use and potential implications on heart health....

Contrave Hearing: FDA Recommends Approval of Weight-Loss Drug

(Dec. 7) -- Is losing weight as simple as taking a pill? The answer may be yes. After a long hearing today, a Food and Drug Administration advisory committee recommended the approval of Contrave, a weight-loss drug developed by La Jolla, Calif.-based pharmaceutical company Orexigen. The FDA is expected to make its final...

FDA Panel Rejects Experimental Weight Loss Pill

GAITHERSBURG, MD. (July 15) -- A panel of federal health experts dealt a surprising setback Thursday to a highly anticipated anti-obesity pill from Vivus Inc., saying the drug's side effects outweigh its ability to help patients lose weight. The Food and Drug Administration panel voted 10-6 against Vivus's Qnexa, citing...

Orexigen Therapeutics Inc News From AOL

THE HUFFINGTON POST

Heart Risks Of Obesity Drugs: U.S. Ponders Safety Trials Before Approval

U.S. health regulators are asking for advice on whether, and when, heart safety studies should be required for new obesity drugs, possibly adding a new hurdle on their path to approval.

Orexigen Therapeutics Inc News From the Web

05/14/12 OrexigenÂ® Therapeutics To Be Added to the NASDAQ... Source: ABC - KAIT K8 - Jonesboro AR Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider.
05/14/12 Mulling Arena Pharma's Future With Obesity Drug on... Source: TheStreet.com Thoughts, questions and reflections on Arena Pharmaceuticals ( ARNA ) following Thursday's FDA advisory panel, which voted 18-4 (with one abstention) to recommend the approval of lorcaserin for weight loss.
05/14/12 Arena and Orexigen Compete to Bring First Weight Loss... Source: StockWatch Biotech companies are looking to cash in on the anti-obesity drug market.
05/14/12 NASDAQ Changes Up Biotech Index Members & Weightings Source: 24/7 Wall Street Index changes are generally speaking a fairly routine event.
05/11/12 24/7 Wall St. Closing Bell Source: 24/7 Wall Street The major US stock indexes opened significantly lower this morning as investors reacted to the surprise loss of $2 billion by JPMorgan Chase & Co. ( NYSE: JPM ) disclosed by the bank's CEO after trading closed last night (more coverage here and on the 24/7 Wall St. Wire ).